Options considerations | IMGN Message Board Posts

ImmunoGen, Inc.

  IMGN website

  • TECH UPDATE: Since we don't serve ads to Premium Members, our "premium" URL is not affected by the new code now required by our ad partners. So, rather than wait for us to resolve all these lovely new code conflicts suddenly plaguing our free, ad-supported "www" pages  (a process which will likely take days), Premium Members can enjoy full site functionality now by simply logging in to their premium accounts at https://premium.investorvillage.com If you need password assistance, don't hesitate to contact us. That's what we're here for.  

IMGN   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  49611 of 49715  at  6/17/2019 2:26:50 PM  by


Options considerations

I've looked at the options and believe the $4 calls for January offer a great chance for tremendous appreciation as IMGN will have numerous opportunities to present positive information between now and then. Should IMGN853 gain a ROW partnership during this time I believe double digits will be seen. Should that occur, without using margin or cash from my account I could add thousands of shares by only selling a small part of the options I purchased.

Over the years I've seen IMGN up and down throughout it's history. I still believe the potential today, depending on what's reported in the many drug trials it and it's partners have running, could be higher than at any other time in it's history. Certainly IMGN853 has been delayed in the U.S., but they won't be denied with a properly designed trial. The question is, will others follow the FDA, or be willing to review the data and recognize a substantial patient group could benefit from the drug today, it makes little sense to deny that. If a partnership occurs for ROW, I believe that partner will convince the authorities that a limited approval, with a Phase 4 required for all who get the drug, will be authorized.

I'm a big believer that all approved drugs should go into a Phase 4 where all results of its use are reported. It doesn't need to be a big effort if unexpected results aren't seen, but it also provides a way of seeing how it's being used off label, and learning about the result there might be the most valuable thing that happens. I don't believe that any new drug doesn't get used off label, either in terms of being tried for other diseases, or being used in ways that differ from the approved protocol for the drug. I believe many can learn from the documentation that could be found in Phase 4, but it would not allow for drug makers to hide bad results under settlements made with confidentiality agreements.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 221
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2018 Investorvillage.com. All rights reserved. User Agreement
Financial Market Data provided by